Why the study?
Does PCSK9 inhibition reduce markers of platelet activation and endothelial dysfunction in ACS patients?
Does PCSK9 inhibition reduce markers of platelet activation and endothelial dysfunction in ACS patients?
PCSK9 inhibition demonstrates potential pleiotropic benefits in ACS by reducing platelet activation and endothelial dysfunction.
May support pleiotropic effects in ACS via surrogate markers; hypothesis-generating and should not change practice.
Proprotein Convertase Subtilisin/Kexin 9 inhibition decreases markers of platelet activation and endothelial dysfunction in ACS patients. PCSK9 is associated with platelets and vascular ECs in LIMA segments and PCSK9 inhibition decreases that interaction.
No takes yet. Share an insight, caveat, or question.
Ziogos et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: